Liver-specific contrast agents.

In the patient with cancer, magnetic resonance imaging is increasingly used as a diagnostic tool for disease detection, lesion characterization, as well as the assessment of treatment response. Although non-contrast T1-weighted and T2-weighted imaging, together with low molecular weight extracellular gadolinium contrast-enhanced T1-weighted magnetic resonance imaging remain the cornerstone for liver assessment, there is increasing recognition of the benefits of liver-specific contrast agents for disease evaluation.